Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat

Brain Research

Volumn 1317, Issue , 2010, Pages 137-146

  Brennan, Katharine A ^a,b   Colussi Mas, Joyce ^b   Carati, Caleb ^b   Lea, Rod A ^a   Fitzmaurice, Paul S ^a   Schenk, Susan ^b  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Contingency; Dopamine; Dopamine turnover; Methamphetamine; Striatum; Yoked self administration

Indexed keywords

DOPAMINE; METHAMPHETAMINE; MONOAMINE; SEROTONIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTINGENT VALUATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FRONTAL CORTEX; INSTRUMENTAL CONDITIONING; MALE; METABOLITE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM; SEROTONIN RELEASE; TISSUE LEVEL; TREATMENT DURATION; TURNOVER TIME;

ANIMALS; CATHETERIZATION; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; FRONTAL LOBE; MALE; METHAMPHETAMINE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; SEROTONIN; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

RATTUS;

EID: 75849162281     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.069     Document Type: Article

References (78)

1. Askew B.M. Hyperpyrexia as a contributory factor in the toxicity of amphetamine to aggregated mice. Br. J. Pharmacol. Chemother. 19 (1962) 245-257
2. Baumann M.H., et al. Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J. Pharmacol. Exp. Ther. 301 (2002) 1190-1197
3. Bortolato M., et al. Methamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotonergic toxicity. Neurotox. Res. 15 (2009) 232-245
4. Bowyer J.F., et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268 (1994) 1571-1580
5. Brennan K., et al. Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend. 88 (2007) 204-213
6. Broening H.W., et al. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 27 (1997) 153-160
7. 2 receptor antagonists with d-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56 (2005) 84-93
8. Cadet J.L., et al. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res. 11 (2007) 183-202
9. Cadet J.L., et al. Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain. Neurotox. Res. 15 (2009) 252-259
10. Cappon G.D., et al. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Brain Res. Dev. Brain Res. 103 (1997) 155-162
11. Chapman D.E., et al. Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J. Pharmacol. Exp. Ther. 296 (2001) 520-527
12. Cho A.K. Ice: a new dosage form of an old drug. Science 249 (1990) 631-634
13. Cho A.K., et al. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39 (2001) 161-166
14. Chu P.W., et al. Differential regional effects of methamphetamine on dopamine transport. Eur. J. Pharmacol. 590 (2008) 105-110
15. Colado M.I., et al. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br. J. Pharmacol. 134 (2001) 1711-1723
16. Danaceau J.P., et al. Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur. J. Pharmacol. 559 (2007) 46-54
17. Davidson C., et al. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. 36 (2001) 1-22
18. Davidson C., et al. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem. Int. 46 (2005) 189-203
19. Dworkin S.I., et al. Rat brain neurotransmitter turnover rates altered during withdrawal from chronic cocaine administration. Brain Res. 682 (1995) 116-126
20. Eisch A.J., et al. Characterizing cortical neuron injury with Fluoro-Jade labeling after a neurotoxic regimen of methamphetamine. Synapse 30 (1998) 329-333
21. Fantegrossi W.E., et al. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151 (2008) 533-543
22. Fitzmaurice P.S., et al. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther. 319 (2006) 703-709
23. Fleckenstein A.E., et al. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J. Pharmacol. Exp. Ther. 283 (1997) 281-285
24. Friedman S.D., et al. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 61 (1998) 35-44
25. Giovanni A., et al. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64 (1995) 1819-1825
26. Gough B., et al. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann. N.Y. Acad. Sci. 965 (2002) 410-420
27. Graham D.L., et al. Differential neurochemical consequences of an escalating dose-binge regimen followed by single-day multiple-dose methamphetamine challenges. J. Neurochem. 105 (2008) 1873-1885
28. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 6 (2006) 6
29. Hauptmann N., et al. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch. Biochem. Biophys. 335 (1996) 295-304
30. Heffner T.G., et al. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13 (1980) 453-456
31. Helkamaa T., et al. Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem. Int. 51 (2007) 412-423
32. Herring N.R., et al. Effect of +-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats. Psychopharmacology (Berl) 199 (2008) 637-650
33. Holschneider, D. P., Shih, J.C., 2000, Monoamine Oxidase: Basic and Clinical Perspectives Psychopharmacology - 4th Generation of Progress, 2000, pp. http://www.acnp.org/g4/GN401000046/Default.htm.
34. Imam S.Z., and Ali S.F. Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J. Neurochem. 78 (2001) 952-959
35. Jacobs E.H., et al. Neuroadaptive effects of active versus passive drug administration in addiction research. Trends Pharmacol. Sci. 24 (2003) 566-573
36. Johnson-Davis K.L., et al. The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur. J. Pharmacol. 482 (2003) 151-154
37. Kil H.Y., et al. Brain temperature alters hydroxyl radical production during cerebral ischemia/reperfusion in rats. J. Cereb. Blood Flow Metab. 16 (1996) 100-106
38. Kitamura O., et al. Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186 (2006) 48-53
39. Kogan F.J., et al. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36 (1976) 363-371
40. Lau C.E., and Sun L. The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. Drug Metab. Dispos. 30 (2002) 254-261
41. Lineberry T.W., and Bostwick J.M. Methamphetamine abuse: a perfect storm of complications. Mayo Clin. Proc. 81 (2006) 77-84
42. Maeda H., et al. Effects of dopamine agonists on hypothalamic defensive attack in cats. Physiol. Behav. 35 (1985) 89-92
43. McCann U.D., et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62 (2008) 91-100
44. Myles B.J., et al. The effects of methamphetamine on core body temperature in the rat-part 1: chronic treatment and ambient temperature. Psychopharmacology (Berl) 198 (2008) 301-311
45. O'Dell S.J., and Marshall J.F. Neurotoxic regimens of methamphetamine induce persistent expression of phospho-c-Jun in somatosensory cortex and substantia nigra. Synapse 55 (2005) 137-147
46. O'Neil M.L., et al. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 60 (2006) 465-473
47. O'Shea E., et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37 (1998) 919-926
48. Pubill D., et al. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch. Pharmacol. 367 (2003) 490-499
49. Quinton M., and Yamamoto B. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J. 8 (2006) E337-347
50. Ricaurte G.A., et al. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235 (1982) 93-103
51. Ricaurte G.A., et al. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303 (1984) 359-364
52. Riddle E.L., et al. Tolerance to the neurotoxic effects of methamphetamine in young rats. Eur. J. Pharmacol. 435 (2002) 181-185
53. Rogers J.L., et al. Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats. Psychopharmacology (Berl) 199 (2008) 615-624
54. Romanelli F., and Smith K.M. Clinical effects and management of methamphetamine abuse. Pharmacotherapy 26 (2006) 1148-1156
55. Schwendt M., et al. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J. Pharmacol. Exp. Ther. 331 (2009) 555-562
56. Segal D.S., and Kuczenski R. Escalating dose-binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses. Psychopharmacology (Berl) 142 (1999) 182-192
57. Segal D.S., et al. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28 (2003) 1730-1740
58. Shankaran M., et al. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40 (2001) 55-64
59. Sharma H.S., and Kiyatkin E.A. Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J. Chem. Neuroanat. 37 (2008) 18-32
60. Shepard J.D., et al. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology (Berl) 185 (2006) 505-513
61. Shintomi K. Effects of psychotropic drugs on methamphetamine-induced behavioral excitation in grouped mice. Eur. J. Pharmacol. 31 (1975) 195-206
62. Sonsalla P.K., and Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 12 (1988) 345-354
63. Stefanski R., et al. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology (Berl) 175 (2004) 68-75
64. Stefanski R., et al. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur. J. Pharmacol. 371 (1999) 123-135
65. Stefanski R., et al. Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration. Eur. J. Pharmacol. 439 (2002) 59-68
66. Thomas D.M., et al. Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J. Neurochem. 109 (2009) 1745-1755
67. Tokunaga I., et al. The peroxidative DNA damage and apoptosis in methamphetamine-treated rat brain. J. Med. Invest. 55 (2008) 241-245
68. UNODC, 2007. United Nations Office of Drugs and Crime: World Drug Report. http://www.unodc.org/pdf/research/wdr07/WDR_2007_executive_summary.pdf.
69. Volz T.J., et al. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 63 (2009) 147-151
70. Wagner G.C., et al. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181 (1980) 151-160
71. Wallace T.L., et al. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J. Neurosci. 19 (1999) 9141-9148
72. Wang Z., and Woolverton W.L. Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl) 189 (2007) 483-488
73. 2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32 (2007) 2238-2247
74. Wei Q., et al. Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J. Neurosci. Res. 46 (1996) 666-673
75. Wilkins, C., et al., 2005. Key findings from the methamphetamine module of the 2005 Illicit Drug Monitoring System (IDMS). http://www.shore.ac.nz/projects/Meth%20Bulletin.pdf (accessed on 12 September 2006).
76. Xi Z.X., et al. A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats. Neuroscience 161 (2009) 392-402
77. Xie T., et al. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 20 (2000) 7838-7845
78. Yokel R.A., and Piekens R. Drug level of d- and l-amphetamine during intravenous self-administration. Psychopharmacologia 34 (1974) 255-264